Literature DB >> 2659667

Trypanosoma cruzi reduces the number of high-affinity IL-2 receptors on activated human lymphocytes by suppressing the expression of the p55 and p70 receptor components.

F Kierszenbaum1, W R Cuna, L A Beltz, M B Sztein.   

Abstract

We previously established that Trypanosoma cruzi, the causative agent of Chagas' disease, has the ability to suppress expression of the p55 component of the IL-2R by activated human PBMC. We explored in this work whether the parasite alters the expression of high affinity IL-2R, responsible for the internalization of IL-2 and signal transduction. Radiobinding measurements revealed that the trypanosome indeed inhibited the expression of high affinity IL-2R. Thus, a considerably smaller number of 125I-IL-2 molecules was necessary to saturate the IL-2R on PHA-stimulated PBMC cocultured with T. cruzi than those of control PBMC that had not been exposed to the organisms. Scatchard analysis of equilibrium binding data showed that, in the presence of T. cruzi, the number of high affinity IL-2R per cell was reduced by approximately 80%. The Kd for IL-2 binding to the fewer IL-2R expressed on PBMC exposed to T. cruzi was not significantly different from that of IL-2R on nonsuppressed PBMC. Independent measurements made after cross-linking 125I-IL-2 to its specific receptors with disuccinimidylsuberate showed that both the p55 and p70 components of the IL-2R were markedly suppressed and to comparable extents. These results demonstrate for the first time that T. cruzi suppresses the expression of high affinity IL-2R by human cells, including the p70 chain of the heterodimeric IL-2R. It is noteworthy that the in vitro model system we used in this work to study the mechanisms whereby T. cruzi may induce the immunosuppression that accompanies acute Chagas' disease also lends itself to the exploration of the regulatory mechanisms governing the expression of IL-2R by human PBMC.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659667

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Trypanosoma cruzi-induced suppression of human peripheral blood lymphocytes activated via the alternative (CD2) pathway.

Authors:  L A Beltz; F Kierszenbaum; M B Sztein
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

2.  Gastric invasion by Trypanosoma cruzi and induction of protective mucosal immune responses.

Authors:  D F Hoft; P L Farrar; K Kratz-Owens; D Shaffer
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

3.  Gamma interferon modulates CD95 (Fas) and CD95 ligand (Fas-L) expression and nitric oxide-induced apoptosis during the acute phase of Trypanosoma cruzi infection: a possible role in immune response control.

Authors:  G A Martins; L Q Vieira; F Q Cunha; J S Silva
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

4.  Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle.

Authors:  B J Shenker; S Datar
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

5.  Trypanosoma cruzi suppresses the expression of the p75 chain of interleukin-2 receptors on the surface of activated helper and cytotoxic human lymphocytes.

Authors:  F Kierszenbaum; M B Sztein
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

6.  Suppression by Trypanosoma brucei rhodesiense of the capacities of human T lymphocytes to express interleukin-2 receptors and proliferate after mitogenic stimulation.

Authors:  F Kierszenbaum; S Muthukkumar; L A Beltz; M B Sztein
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

7.  Impairment of monocytic function during Trypanosoma cruzi infection.

Authors:  M J Louie; W R Cuna; C Rodriguez De Cuna; L Mayer; K Sperber
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

8.  Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection.

Authors:  J S Silva; P J Morrissey; K H Grabstein; K M Mohler; D Anderson; S G Reed
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.